US Bancorp
EWTX icon

US Bancorp’s Edgewise Therapeutics EWTX Stock Holding History

US Bancorp’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$138K Buy
3,386
+413
+14% +$14.2K ﹤0.01% 2289
2026
Q1 		$93.6K Buy
2,973
+1,409
+90% +$40.6K ﹤0.01% 2423
2025
Q4 		$38.8K Sell
1,564
-728
-32% -$14.6K ﹤0.01% 2807
2025
Q3 		$37.2K Buy
2,292
+283
+14% +$4.01K ﹤0.01% 2800
2025
Q2 		$26.3K Sell
2,009
-1,204
-37% -$17.4K ﹤0.01% 3068
2025
Q1 		$70.7K Sell
3,213
-96
-3% -$2.52K ﹤0.01% 2568
2024
Q4 		$88.4K Sell
3,309
-5,227
-61% -$166K ﹤0.01% 2454
2024
Q3 		$228K Buy
8,536
+8,468
+12,453% +$168K ﹤0.01% 1970
2024
Q2 		$1.22K Hold
68
– – ﹤0.01% 3782
2024
Q1 		$1.24K Buy
+68
New +$1.08K ﹤0.01% 3795
2023
Q4 		– Sell
-180
Closed -$1.03K – 4038
2023
Q3 		$1.03K Sell
180
-304
-63% -$2.07K ﹤0.01% 3761
2023
Q2 		$3.75K Buy
+484
New +$4.08K ﹤0.01% 3555
2023
Q1 		– Sell
-236
Closed -$2.11K – 4119
2022
Q4 		$2.11K Buy
+236
New +$2.21K ﹤0.01% 3759

Other funds holding EWTX

OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Paradigm Biocapital Advisors
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jupiter Topco
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Novo Holdings A/S
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 107.05% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

US Bancorp's EWTX Position: Q2 2026 in Review

US Bancorp increased its Edgewise Therapeutics (EWTX) stake by 14% in Q2 2026, buying an estimated $14.2K and bringing the position to 3,386 shares worth $138K. The position accounts for ﹤0.01% of the portfolio, ranked #2289.

US Bancorp first reported a position in EWTX in Q4 2022 and has held it in 13 quarters since. The position peaked at $228K in Q3 2024. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • US Bancorp held 3,386 shares of Edgewise Therapeutics worth $138K as of Q2 2026.
  • US Bancorp bought 413 Edgewise Therapeutics shares in Q2 2026, an estimated $14.2K.
  • Edgewise Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #2289 holding.
  • US Bancorp first reported a position in Edgewise Therapeutics in Q4 2022 and has held it in 13 quarters since.
  • US Bancorp's Edgewise Therapeutics position peaked at $228K in Q3 2024.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.